Table 2. Univariable odds ratios of possible risk factors for the detection of ≥1 adenoma within the derivation and validation cohort.
| Possible predictors | Derivation cohort | Validation cohort |
|---|---|---|
| Univariable odds ratioa [95%-CI] |
Univariable odds ratioa [95%-CI] |
|
| Age (per year increase) | 1.03 [1.02–1.04] | 1.02 [1.02–1.03] |
| Female | 1.00 (ref) | 1.00 (ref) |
| Male | 1.79 [1.64–1.94] | 1.57 [1.44–1.70] |
| BMI (per kg/m2 increase)b | 1.02 [1.01–1.03] | 1.03 [1.02–1.04] |
| ASA I | 1.00 (ref) | 1.00 (ref) |
| ASA II | 1.43 [1.30–1.58] | 1.32 [1.19–1.47] |
| ASA III or IVc | 1.95 [1.66–2.30] | 1.19 [0.98–1.44] |
| Race | ||
| Otherd | 1.00 (ref) | 1.00 (ref) |
| African-American or black | 1.04 [0.91–1.17] | 0.84 [0.72–0.98] |
| Asian | 1.06 [0.73–1.50] | 0.73 [0.51–1.02] |
| Unknown or patient declined to provide | 1.10 [0.99–1.22] | 0.51 [0.44–0.60] |
| Ethnicity | ||
| Not Hispanic or Latino | 1.00 (ref) | 1.00 (ref) |
| Hispanic or Latino | 1.13 [1.00–1.27] | 0.78 [0.49–1.20] |
| Unknown or patient declined to provide | 1.12 [1.02–1.23] | 0.63 [0.56–0.71] |
| Indication for colonoscopye | ||
| Screening | 1.00 (ref) | 1.00 (ref) |
| Surveillance | 1.67 [1.53–1.83] | 1.56 [1.44–1.70] |
| History of colorectal cancer | ||
| No | 1.00 (ref) | 1.00 (ref) |
| Familyf | 0.88 [0.75–1.02] | 1.13 [0.97–1.31] |
| History of colorectal adenomas | ||
| No | 1.00 (ref) | 1.00 (ref) |
| Familyf | 1.12 [0.93–1.35] | 1.17 [0.88–1.55] |
ASA, American Society of Anesthesiology physical status class; BMI, body mass index; CI, confidence interval; ref, reference category.
aOdds ratios based on a univariable logistic regression model with detection of ≥1 adenoma as outcome. 95% confidence intervals are profiled confidence intervals.
bThis association is calculated after multiple imputation.
cOnly three patients in the development cohort and no patients in the validation cohort were in ASA category IV and therefore ASA III and IV were combined.
dIncluding white, native American, Alaska native, native Hawaiian and native Pacific patients and patient’s race categorized as other.
eThe indication is considered surveillance for patients with a personal history of colorectal adenomas or surveillance marked as indication on the GastroIntestinal Quality Improvement Consortium (GIQuIC) form.
fFamily history is defined as a first degree relative diagnosed with the condition at an age <60 years.